BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20444041)

  • 1. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
    Yancey MF; Merritt DA; White JA; Marsh SA; Locuson CW
    J Vet Pharmacol Ther; 2010 Apr; 33(2):154-61. PubMed ID: 20444040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of dirlotapide in the dog.
    Merritt DA; Lynch MP; King VL
    J Vet Pharmacol Ther; 2007 Aug; 30 Suppl 1():24-32. PubMed ID: 17567512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
    Boothe DM; Perkins J
    J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer drug approved for dogs.
    J Am Vet Med Assoc; 2009 Jul; 235(2):139. PubMed ID: 19610240
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of florfenicol and its metabolite, florfenicol amine, in dogs.
    Park BK; Lim JH; Kim MS; Hwang YH; Yun HI
    Res Vet Sci; 2008 Feb; 84(1):85-9. PubMed ID: 17570454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Suitability of the peroral administration of the marker creatinine for the quantitative determination of the glomerular filtration rate (GFR) in dogs].
    Hartmann H; Baumgardt T; Höchel J
    Berl Munch Tierarztl Wochenschr; 2006; 119(1-2):62-7. PubMed ID: 16450711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs.
    Cox SR; Lesman SP; Boucher JF; Krautmann MJ; Hummel BD; Savides M; Marsh S; Fielder A; Stegemann MR
    J Vet Pharmacol Ther; 2010 Oct; 33(5):461-70. PubMed ID: 20840390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.
    Kukanich B; Lascelles BD; Aman AM; Mealey KL; Papich MG
    J Vet Pharmacol Ther; 2005 Oct; 28(5):461-6. PubMed ID: 16207309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus).
    Abu-Basha EA; Gehring R; Hantash TM; Al-Shunnaq AF; Idkaidek NM
    J Vet Pharmacol Ther; 2009 Jun; 32(3):258-63. PubMed ID: 19646090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.